Theramab LLC
Records under this name other than patents Theramab LLC holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Showing 1 to 10 of 10 · Back to Theramab LLC
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,585,960 | Nucleic acids encoding superagonistic anti-CD28 antibodies Term ended Term ended May 11, 2026 · From the USPTO record | Term ended | Term ended May 11, 2026 | From the USPTO record |
| US 8,709,414 | Superagonistic anti-CD28 antibodies Lapsed on the fee record Ended Apr 29, 2026 · From the USPTO record | Lapsed on the fee record | Ended Apr 29, 2026 | From the USPTO record |
| US 8,034,585 | Superagonistic anti-CD28 antibodies Lapsed on the fee record Ended Oct 11, 2023 · From the USPTO record | Lapsed on the fee record | Ended Oct 11, 2023 | From the USPTO record |
| US 9,119,840 | Use of an active substance binding to CD28 for producing a pharmaceutical composition for activating and expanding T cells Lapsed on the fee record Ended Sep 1, 2023 · From the USPTO record | Lapsed on the fee record | Ended Sep 1, 2023 | From the USPTO record |
| US 7,939,638 | Superagonistic anti-CD28 antibodies Lapsed on the fee record Ended May 10, 2023 · From the USPTO record | Lapsed on the fee record | Ended May 10, 2023 | From the USPTO record |
| US 7,868,143 | Microparticle with cd28-specific monoclonal antibodies Lapsed on the fee record Ended Jan 11, 2023 · From the USPTO record | Lapsed on the fee record | Ended Jan 11, 2023 | From the USPTO record |
| US 8,586,386 | Peptide or protein comprising a C′-D loop of the CD28 receptor family Lapsed on the fee record Ended Nov 19, 2021 · From the USPTO record | Lapsed on the fee record | Ended Nov 19, 2021 | From the USPTO record |
| US 8,389,016 | Use of a CD28 binding substance for making a pharmaceutical composition Lapsed on the fee record Ended Mar 5, 2021 · From the USPTO record | Lapsed on the fee record | Ended Mar 5, 2021 | From the USPTO record |
| US 8,334,102 | Human CD28 specific monoclonal antibodies for antigen-nonspecific activation of T-lymphocytes Formerly held Term ended Term ended May 28, 2018 · From the USPTO record | Term ended | Term ended May 28, 2018 | From the USPTO record |
| US 6,987,171 | Human CD28 specific monoclonal antibodies for antigen-non-specific activation of T-lymphocytes Lapsed on the fee record Ended Jan 17, 2018 · From the USPTO record | Lapsed on the fee record | Ended Jan 17, 2018 | From the USPTO record |